Award

Repurposing Metformin to Target TET2 Mutation Driven Clonal Hematopoiesis and Malignant Transformation

Description: Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the expansion of blood cells carrying mutations associated with leukemia in individuals without evidence of a blood disorder. One of the most common CHIP mutations is in the gene TET2. Individuals with CHIP are at a substantially higher risk of developing blood cancers than non-carriers. The time period from CHIP to a diagnosis of blood cancer can be many years. This finding opens up the intriguing possibility of intervening to prevent blood cancers from developing in the first place. To achieve this goal, safe and effective interventions are needed. Here, we will explore the preventive potential of metformin, a safe and commonly-used diabetic medication, in suppressing TET2 mutation-driven CHIP. Mutations in TET2 reduce the activity of TET2, which in turn causes the expansion of mutated blood cells. We recently discovered that metformin is able to restore TET2 expression and activity and suppress the growth of TET2-mutated cells. In this proposal, we will build on these findings by exploring how metformin works. We will study the role of a protein called AMPK and determine how metformin changes the genetic code in TET2-mutated cells. Finally, we will determine if metformin treatment can prevent or delay the development of leukemia in a mouse model of CHIP. Our proposed studies, if successful, will establish a novel approach for preventing blood cancers.
Amount: CA$573,800
Funding type: research
Funder scheme: Project Grant
Start date: 2021-04-01
End date: 2025-03-31
Investigator: Steven Chan (lead)
Institutions: University Health Network, University Health Network (Toronto)
Subfield: Hematology
Field: Medicine
Funded outputs count: 1
Funder award ID: 175186_1
OpenAlex ID: G5520290448